Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Accumulating evidence has shown that angiopoietin-like-3 (ANGPTL3) plays pivotal roles in biological processes and pathological changes, including kidney diseases. ANGPTL3 expression is overexpressed in patients with proteinuria and glomerular disease. ANGPTL3 up-regulation increases podocyte motility via changes in the expression of nephrin and inducing f-Actin rearrangement, and its suppression mitigates pathological changes in kidney diseases via reducing the apoptotic cells, detached cells, and podocyte loss. Moreover, ANGPTL3 suppression can protect podocytes from injury by inhibiting the ROS/GRP78 signaling pathway in acute kidney injury. ANGPTL3 can indirectly participate in renal pathology by inducing hyperlipidaemia and inflammation. In general, ANGPTL3 inhibition holds promising therapeutic potential for management of kidney diseases, especially those linked to lipid abnormalities. However, it is essential to carefully evaluate potential side effects of ANGPTL inhibitors to guarantee their effective and safe use in clinical settings. The present review summarizes existing knowledge on the role of ANGPTL3 in kidney diseases and ANGPTL3-inhibiting therapies that can be considered as potential treatments for kidney diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2025.118189 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ADAM9 Promotes Glycolysis in Th17 Cells and Autoimmunity Through Activation of IGF-1 Signaling.
Arthritis Rheumatol
July 2025
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Objective: Interleukin-17-producing CD4 Th17 cells contribute to the pathogenesis of autoimmune diseases, including crescentic glomerulonephritis. Although ADAM9 has been reported to contribute to organ inflammation, the mechanism remains poorly understood. The goal of the current study was to investigate how ADAM9 alters T cell metabolism to promote the generation of Th17 cell differentiation.
View Article and Find Full Text PDFThe relationship among inflammatory biomarkers, hyperuricemia and chronic kidney disease: analysis of the NHANES 2015-2020.
Ren Fail
December 2025
Department of Nephrology, The First Hospital of Jilin University, Changchun, China.
Background: Inflammation and hyperuricemia are closely associated with chronic kidney disease (CKD). The systemic inflammation response index (SIRI), systemic immune-inflammation index (SII), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are emerging as novel biomarkers. While, the synergistic effects of these biomarkers with hyperuricemia on CKD remain unclear.
View Article and Find Full Text PDFShiga Toxin Type 2 Aggravates G1/S Phase Cell Cycle Arrest, Mediating Caspase-Independent Cell Death under Hyperosmotic Conditions in the Kidney.
J Microbiol Biotechnol
September 2025
Environmental Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea.
Shiga toxin (Stx) is a virulence factor produced by serotype 1 and Stx-producing (STEC). It causes severe renal damage, leading to hemolytic uremic syndrome (HUS). The main target organ of Stx, the kidney, plays a role in maintaining water homeostasis in the body by increasing an osmotic gradient from the cortex to the medulla.
View Article and Find Full Text PDFQuantitative Susceptibility Mapping for Evaluating Renal Functional Injury in Chronic Kidney Disease Patients: A Pilot Study.
NMR Biomed
October 2025
Department of Radiology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Chronic kidney disease (CKD) is an increasing global health problem, resulting in gradual loss of renal function and irreversible renal injury. The noninvasive detection, monitoring, and timely intervention of CKD might benefit the patients' prognosis. This study aims to assess renal functional injury in CKD patients by using magnetic resonance imaging (MRI) of quantitative susceptibility mapping (QSM).
View Article and Find Full Text PDFTRAP1 and its therapeutic potential.
Bioorg Med Chem Lett
September 2025
Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, United States. Electronic address:
The mitochondrial Hsp90 isoform, Tumor Necrosis Factor Receptor Associated Protein 1 (TRAP1), is central to the pathogenesis of disease states that include cancer, ischemic retinopathy, and diabetic kidney disease among others. TRAP1 contributes to these diseases through the regulation of mitochondrial metabolism, apoptosis, oxidative stress, cell signaling and angiogenesis through interactions with client proteins. Numerous TRAP1-selective inhibitors have been developed to limit the toxicities associated with Hsp90 pan-inhibition, while leveraging the therapeutic benefits of TRAP1 inhibition.
View Article and Find Full Text PDF